Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus nab-paclitaxel and gemcitabine for first-line pancreatic adenocarcinoma with synchronous liver metastases
ChiCTR2000033819Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital Ethics Committee
- Start
- Jul 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Ruijin Hospital Ethics Committee. Primary endpoint: Progression-free survival. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
camrelizumabpaclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2000033819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033819.